Omakase Consulting will be part of a new initiative to value the clinical benefits of oncological drugs. Oncovalor Group will be a permanent multidisciplinary group that will provide advice to decision makers.

To read the full article, click on the following link:

2019-05-02T08:34:00+00:00May 2nd, 2019|News|

This website uses cookies so that you have the best user experience. If you continue browsing you are giving your consent for the acceptance of the aforementioned cookies and the acceptance of our cookies policy, Click on the link for more information. ACEPTAR

Aviso de cookies